Navigation Links
Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections

RARITAN, New Jersey, December 18, 2015 /PRNewswire/ --

New approach for early treatment and interception of HPV-induced cancers  

Janssen Pharmaceuticals, Inc. (Janssen) announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN®  technology, jointly with Janssen's own AdVac® technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.  Under this agreement, Janssen will conduct all clinical development and, subject to regulatory approval, will be responsible for registration, distribution and commercialization of the potential combination vaccine worldwide.  


Despite a recent focus on the prevention of infection for certain HPV types, a large population remains at risk of HPV-related cancers.  Janssen will leverage the prime-boost approach, similar to that used in its Ebola vaccine regimen which is currently in Phase 3 clinical trials. This approach has shown to induce a strong and longer-lasting immune response, demonstrated by both increased antibodies and T cell responses. The goal is to develop a therapeutic vaccine which aims to intercept HPV infection-related disease, particularly in women and men who are diagnosed with HPV early, by enhancing the ability of the immune system to treat chronic infections and prevent progression to cancer.  

"HPV carries a significant disease burden, which can be addressed by intercepting disease progression and treating the viral infection," says Johan Van Hoof, M.D., Global Head, Infectious Diseases and Vaccines, Janssen. "We are bringing together our technology with that of Bavarian Nordic to develop a potentially first-in-class HPV vaccine which could advance human health by reducing the number of new cancer cases and associated deaths."

HPV-related cancers, which occur when a chronic infection of some HPV types cause changes to infected cells, are responsible for over 650 thousand cases globally[1] each year.  HPV is the primary cause of cervical cancer and certain types of head and neck cancer, in addition to several rare cancers.  

With over 300 million estimated infections among men and women annually, HPV is the most prevalent sexually transmitted disease in the world.  

About the Janssen Pharmaceutical Companies of Johnson & Johnson 

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.  Janssen Pharmaceuticals, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking Statements 

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding a new collaboration and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals, Inc. and Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.


1. Global Burden of Human Papillomavirus and Related Diseases, Forman et al, Vaccine , July 2012

Press Contacts:
Daniel De Schryver
Ronan Collins

Investor Contacts:
Louise Mehrotra
Lesley Fishman

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Janssen to Showcase Growing Portfolio with More Than 40 Data Presentations at the 2015 American Society of Hematology (ASH) Annual Meeting
2. Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
3. Leitender Neurowissenschaftler bei Janssen in den Wissenschaftlichen Beirat des globalen Dementia Discovery Fund bestellt
4. Janssen Tackles Mental Health Stigma in New Healthy Minds Videos
5. U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma
6. New Study by TSRI and Janssen Makes Major Advance Toward More Effective, Long-Lasting Flu Vaccine
7. Black Celebrities Come Out to Honor 2015 Heroes in the Struggle Honoring Jussie Smollett, Gregorio Millett, Vanessa Mills, and Janssen Therapeutics
8. Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma
9. PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato
10. PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert
11. PharmaMar annonce que létude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé
Post Your Comments:
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):